Pseudobulbar Affect: Causes and Treatment
For pseudobulbar affect, use dextromethorphan/quinidine (20 mg/10 mg twice daily), which is FDA-approved and provides the most effective treatment, combined with cognitive-emotional therapy and patient education. 1
What Causes Pseudobulbar Affect
Pseudobulbar affect (PBA) results from disruption of the corticopontine-cerebellar circuit that normally modulates emotional expression 2, 3. This is a network-level disorder of emotional expression, not a mood disorder—patients experience involuntary laughing or crying that is disconnected from their actual emotional state 4, 5.
Primary Neurological Causes:
- Stroke (incidence 10-48% post-stroke) 1
- Traumatic brain injury 2, 4
- Amyotrophic lateral sclerosis (ALS) 6
- Multiple sclerosis 6
- Brain tumors requiring resection 2
Pathophysiology:
The condition arises from bilateral corticobulbar tract degeneration and dysregulation of serotonergic and glutamatergic neurotransmitter systems 5, 7. Structural damage to brainstem regions, particularly the pons, frequently triggers symptoms 2. Dysphagia and abnormal jaw jerk reflex are strongly associated (odds ratios of 14 and 19.8 respectively), indicating pseudobulbar motor dysfunction 7.
How to Treat Pseudobulbar Affect
First-Line Pharmacological Treatment:
Dextromethorphan/quinidine (Nuedexta) 20 mg/10 mg twice daily is the FDA-approved treatment and should be the primary pharmacological intervention 1. This combination:
- Significantly reduces PBA episode frequency compared to placebo 6
- Provides rapid and often complete symptom resolution 2
- Improves Center for Neurologic Study-Lability Scale (CNS-LS) scores 6
- Is generally well tolerated, though monitor for QTc prolongation 6
Non-Pharmacological Interventions:
The guidelines emphasize a multimodal approach 1:
- Cognitive and emotional therapy
- Psychotherapy and support groups
- Patient and family education about the condition—this is critical as most patients are unaware PBA is common in their neurological condition 7
- Acknowledgment and education can defuse potentially uncomfortable social situations 1
Assessment Tools:
Use validated scales for diagnosis and monitoring 1:
- Pathological Laughing and Crying Scale
- Center for Neurological Study-Lability Scale (CNS-LS)
Alternative Pharmacological Options:
If dextromethorphan/quinidine is contraindicated or unavailable, consider:
- SSRIs (though not studied in controlled trials for PBA) 2
- Tricyclic antidepressants like amitriptyline (limited evidence, often ineffective) 2
Critical Clinical Pitfalls
Do not mistake PBA for depression or other mood disorders—this is the most common diagnostic error 4. Key distinguishing features:
- PBA episodes are involuntary and disconnected from internal emotional state
- Laughing is often more prevalent than crying (85% vs 69%) 7
- Symptoms correlate with pseudobulbar motor signs (dysphagia, abnormal jaw jerk) 7
- PBA symptoms appear after motor manifestations, never before 7
Screen early for PBA in all patients with stroke or neurological conditions affecting the brainstem 1. Delayed diagnosis significantly impacts quality of life and leads to social isolation 4, 7.
Monitor for comorbid depression—up to one-third of stroke patients develop depression, which can coexist with PBA but requires separate treatment 1, 8.